A feasibility study of paclitaxel 225 mg/m(2) and carboplatin AUC = 6 in untreated advanced non-small cell lung cancer patients in Japan.

摘要: Background The combination of paclitaxel (225 mg/m(2), 3 h infusion) and carboplatin [area under the curve (AUC) 6 mg/ml x min] is used widely for non-small cell lung cancer in USA one standard regimens Southwest Oncology Group. In Japan, however, upper limit approved dose single-use 210 mg/m(2) optimum this agent with has not yet been established. This study was designated to determine whether 225 mg/m(2 ) plus (AUC = 6) tolerable Japanese patients untreated advanced cancer. Methods Ten were enrolled between October 1999 June 2000 all these evaluable toxicity. Chemotherapy consisted min) )of on day 1 every weeks. Results Neutropenia major toxicity grade 4 neutropenia observed seven 10 (70%), but febrile observed. Grade anemia as a dose-limiting two patients. due gastric ulcer bleeding both Only patient experienced peripheral neuropathy. No or more myalgia arthralgia reported. Overall, 44 courses chemotherapy administered Partial responses six (60%). Median survival time 7.7 months. Conclusion Paclitaxel at infusion AUC appears be